CSL Receives FDA Approval for ANDEMBRY Treatment
CSL, an Australian biotechnology company, has received FDA approval for its ANDEMBRY treatment, a therapy for patients aged 12 and above with hereditary angioedema (HAE).
The FDA approval marks a significant development in the field of HAE prophylaxis.
Key Financial Metrics
- CSL’s stock price has fluctuated within a 52-week range of AUD228.61 to 313.55.
- Current stock price: AUD238.86
- Price-to-earnings ratio: 27.47
- Price-to-book ratio: 4.05
These financial metrics indicate a moderate valuation of the company.